

Company Overview

CytoDyn is a publicly traded clinical stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Leronlimab is being studied for oncology and inflammation.

Our current business strategy is the clinical development of leronlimab, which includes the following:

- i. Conduct studies exploring leronlimab and its therapeutic potential in oncology, including a Phase II trial of leronlimab in patients with relapsed/refractory micro-satellite stable colorectal cancer;
- ii. Conduct studies exploring leronlimab and its effects on inflammation; and
- iii. Continue our work researching and developing a new or modified long-acting version of leronlimab.

Other current programs that may be pursued include liver or other organ fibrosis, either alone or as a combination therapy.

CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab

Jul 1 2025, 8:30 AM EDT

CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer

Jun 24 2025, 8:30 AM EDT

CytoDyn Releases ESMO Breast Cancer Meeting Poster

May 15 2025, 8:30 AM EDT

Stock Overview

Symbol	CYDY
Exchange	OTCQB
Market Cap	371.71m
Last Price	\$0.29
52-Week Range	\$0.10 - \$0.49

08/22/2025 07:59 PM EDT

CytoDyn Inc.

1111 Main Street
Suite 660
Vancouver, WA 98660

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.